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cute HIV-1 infection. Additional data will be presented on
unctional avidity, phenotyping and kinetics across the group
ver the ﬁrst 6 months of infection. Discussion will focus on
ow these results, together with the studies investigating
ew immunogens may direct more effective design of HIV-1
cell vaccines. Supported by the NIAD Center for HIV/AIDS
accine Immunology grant # U19 AI067854.
oi:10.1016/j.ijid.2010.02.1528
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nderstanding Anti-HIV Antibody Targets
. Moore1,∗, E. Gray2, M. Madiga2, N. Ranchobe2, B.
ambson2, M.-R. Abrahams3, G. Bandawe3, D. Sheward3,
. Thebus3, K. Mlisana4, S. Abdool Karim4, C. Williamson3,
. Morris 2
Johannesburg, South Africa
NICD, Johannesburg, South Africa
Institute of Infectious Disease and Molecular Medicine,
niversity of Cape Town, Cape Town, South Africa
Centre for the AIDS Programme of Research in South Africa
CAPRISA), University of KwaZulu Natal, Durban, South
frica
HIV-1 subtype C viruses elicit potent but highly type-
peciﬁc neutralizing antibodies within the ﬁrst year of
nfection. In order to determine the speciﬁcity and evolution
f these autologous neutralizing antibodies, we examined
eutralization escape in four individuals infected with HIV-
subtype C from the CAPRISA 002 cohort in Durban, South
frica. Early neutralizing responses recognized a very lim-
ted number of epitopes, with antibodies that recognize new
pitopes evolving sequentially. In addition, only two regions
f the envelope were targeted by these antibodies, sug-
esting there might be common vulnerabilities in the HIV-1
ubtype C transmitted envelope. We have shown that type-
peciﬁc responses have a short term affect on viral load
hich is lost with the emergence of viral escape mutants.
actors that contribute to the development of broadly cross-
eactive neutralizing antibodies, those which would ideally
e elicited by an HIV vaccine, are largely unknown. We
ave examined the evolution of neutralization breadth in
he CAPRISA 002 cohort, and shown that cross-neutralizing
ntibodies develop in about a quarter of infected individuals
y 3 years post-infection. Generally breadth develops incre-
entally suggesting the possibility that multiple antibodies
ediate breadth, and/or that breadth is conferred by the
aturation of a single speciﬁcity. In one case, the develop-
ent of breadth could be attributed to a single neutralizing
ntibody speciﬁcity. In the CAPRISA 002 cohort, as well as in
cross-sectional cohort of chronically infected individuals,
e have explored the targets of cross-reactive antibodies
hich mediate breadth using an array of methodologies
ncluding peptide and protein adsorptions and the use of
himeric viruses. We have shown that multiple epitopes on
he envelope glycoprotein are involved in the cross-reactive
eutralization elicited during natural HIV-1 infection, many
f which are yet to be determined.
oi:10.1016/j.ijid.2010.02.1529 i
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he Hope and Progress in Microbicides and Pre-Exposure
rophylaxis to Prevent HIV
. Ndase1,∗, S. Hillier2, C. Celum3
Infectious Diseases Institute, Kampala, Uganda
Magee-Womens Hospital„ Pittsburgh, PA, USA
University of Washington, Seattle, WA, USA
Even with a growing recognition that HIV doesn’t dis-
riminate by race, gender, socioeconomic status or sex
rientation, the developing world accounts for 90% of the
lobal HIV burden. Sub-Saharan Africa, which accounts for
wo-thirds of the global HIV infections, Injecting Drug Users,
en who have Sex with Men, and Commercial Sex Workers
are a disproportionate burden of the HIV epidemic. Recent
IV surveillance studies in African countries at best show
tabilization of the epidemic or at worst, slight increases in
ountries like Uganda.
Clearly, the HIV research community recognizes that
dditional new biomedical prevention modalities are
equired to augment existing HIV prevention strategies.
Incidence modeling based on as relatively low efﬁcacy
s 30% for a Pre-Exposure Prophylaxis (PrEP) regimen or a
opical Microbicide has provides a glimmer of hope based on
umber of new HIV infections prevented through such new
odalities. However, scientists need to prove efﬁcacy for
hese new regimens ﬁrst.
Several international collaborations with the develop-
ng world have been formed to enable us conduct clinical
esearch that meets international standards. Phase IIB and
hase III HIV PrEP and Microbicide trials are being conducted
n nine countries globally, involving over 20,000 participants
n the various high risk groups and across different HIV
ransmission routes. Each study is being overseen by regula-
ory agencies both within the developing and the developed
orld.
The major lessons learned to date are that; North-South
ollaborative partnerships are critical to realizing the hope
f ﬁnding new prevention modalities to be added to the HIV
revention tool kit for the most-at-risk groups. Secondly,
ith these collaborations, the developing world has devel-
ped capacity to conduct of clinical research that conforms
o international standards for licensure of new products or
hange of indication of existing drugs/products in the devel-
ping world.
oi:10.1016/j.ijid.2010.02.1530
he H1N1 inﬂuenza pandemic (Invited Presenta-
ion)
8.001
istorical perspective: Lessons Learned from past Pan-
emics
. MorensNIAID, NIH, Bethesda, MD, USA
It has been exactly 500 years since the ﬁrst recognized
nﬂuenza pandemic appeared and spread around the world
n 1510. Since that time, at least 13 additional inﬂuenza
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which will be reported country by country onto a global plat-
form which will allow more systematic monitoring of both
pandemic and seasonal inﬂuenza.
doi:10.1016/j.ijid.2010.02.153314th International Congress on Infectious Diseases (ICID) Abs
pandemics have been studied by countless historians, physi-
cians and scientists. Inﬂuenza and its complications have
been well characterized clinically, much has been learned
about pandemic epidemiology, and a lore about inﬂuenza
pandemic behavior has developed over these past ﬁve
centuries. This includes ideas about pandemic genesis, pan-
demic cycling, and pandemic wave-like behavior. However
today, in the genomics era, much of what we thought we
knew is beginning to unravel, and we are quickly discard-
ing old ideas to replace them with rapidly expanding new
knowledge. Pandemic inﬂuenza was examined using his-
torical research approaches incorporating modern scientiﬁc
methods to develop a comprehensive overview.
In recent years we have come to understand that there
are at least several different mechanisms by which pan-
demic inﬂuenza viruses may be generated, that pandemic
cyclicity is probably partly if not wholly a myth, that pan-
demics may be regional or global, that for most of the
past 500 year domestic animals have played a major role in
inﬂuenza epidemiology, that wave-like pandemic behavior
is not inevitable and probably not wholly a viral property,
and that inﬂuenza co-pathogenesis with common coloniz-
ing nasopharyngeal bacteria probably accounts for most
inﬂuenza-related deaths.
Much remains to be learned about pandemic inﬂuenza,
and we can expect an explosion of knowledge in the coming
decade. It is truly a time to fasten our seatbelts, because
the roller coaster is leaving the platform.
doi:10.1016/j.ijid.2010.02.1531
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The H1N1 Outbreak in Mexico
S. Ponce de Leon
Mexico, Mexico
On April 23rd 2009, health authorities in Mexico informed
that a new virus was causing an increasing number of severe
pneumonia cases in adults with unusually high mortality.
After three weeks of intensive clinical and epidemiologi-
cal research, a new inﬂuenza virus was identiﬁed as the
unknown pathogen in most of the clinical samples sent by
Mexico to labs in Winnipeg and Atlanta. The WHO was noti-
ﬁed on the night of the 22nd, as soon as the information
on etiology was available. At the same time, strict distanc-
ing measures were initiated in Mexico City and its suburbs;
schools were closed and noncritical activities suspended.
The problem was ﬁrst evident at the Emergency Room
of the National Institute of Respiratory Diseases, and con-
ﬁrmed by simultaneous reports received from San Luis Potosi
and Oaxaca. We focused our analysis on cases with severe
viral pneumonia and thus overestimated the mortality of the
virus during the ﬁrst weeks of the outbreak — the full pic-
ture was apparent only afterwards. The initial response was
timely as oseltamivir, educational materials, and protective
medical equipment were ready to be sent thanks to Mex-
ico’s national preparedness plan for a pandemic. 1340 cases
fulﬁlled the case deﬁnition during the ﬁrst month. Mexico’s
strict social distancing measures had a signiﬁcant impact on
the number of cases but were later relaxed. The epidemic
curve shows a sharp increase, followed by a decrease in thets e21
umber of cases, with growth during June and July due to a
igh number of cases in the southeast region. More recently,
nother wave of increased transmission was present in the
etropolitan area.
A signiﬁcant feature of this outbreak has been the
ncreased mortality in patients between 15 and 55 years
ld, some previously healthy, with no increase in the young
nd the old population. Pregnancy and obesity have also
een identiﬁed as risk factors for severity. Previous immunity
robably plays a role in the severity related to age.
Many lessons should be learned from this epidemic: Col-
aboration, preparedness, transparency, and the importance
f being alert towards the unexpected.
oi:10.1016/j.ijid.2010.02.1532
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lobal Surveillance of the H1N1 Pandemic
.W. Mounts
WHO, Geneva, Switzerland
Pandemic surveillance can be viewed from two perspec-
ives, the need to detect the emergence of a novel strain
f inﬂuenza virus and the need to monitor the progression
f spread of the virus. In monitoring pandemic progression,
he primary goal is to describe and detect changes in sev-
ral important epidemiological characteristics of the event.
hese include severity, both in terms of virulence and impact
n society, transmission dynamics, risk groups, and the clini-
al characteristics and spectrum of disease. Several methods
re used for doing this at the global level. These include
he existing network of National Inﬂuenza Center laborato-
ies through FluNet; monitoring of reports from ministries of
ealth both on web sites and formal submissions; monitor-
ng of media reports, formal communications through WHO
ountry ofﬁces and national focal points for International
ealth Regulations; formal networks of epidemiologists,
irologists, and clinicians; and through informal networks
f friends, colleagues, and acquaintances. Several short-
omings have been highlighted by the current pandemic
ncluding lack of standardization for reporting of a vari-
ty of parameters, lack of standard surveillance methods
or severe disease, lack of a requirement for reporting of
ata once initial notiﬁcation occurs, and the challenge of
etting timely data when countries are busy responding to
public health emergency. WHO has proposed a system of
entinel surveillance for severe acute respiratory infections
